至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Oncogenes hijack a constitutively active TP53 promoter in osteosarcoma

biorxiv. 2020-04; 
Karim H. Saba, Louise Cornmark, Michal Kovac, Linda Magnusson, Jenny Nilsson, Hilda van den Bos, Diana C. J. Spierings, Mahtab Bidgoli, Tord Jonson, Vaiyapuri P. Sumathi, Otte Brosjö, Johan Staaf,  View ORCID ProfileFloris Foijer, Emelie Styring, Michaela Nathrath, Daniel Baumhoer,  View ORCID ProfileKarolin H. Nord
Products/Services Used Details Operation
Custom Vector Construction … Cell model to determine TP53-ROR2 responsiveness to DNA damage 5 A promoter-less vector (pSMPUW Universal Lentiviral Expression Vector, Cell Biolabs, Inc., San Diego, CA) containing the TP53-ROR2 fusion was constructed (GenScript, Piscataway, NJ). The … Get A Quote

摘要

The malignant bone tumor osteosarcoma harbors an extreme number of chromosome rearrangements. How such massive DNA errors confer a competitive advantage to a cancer cell has remained an enigma. Osteosarcoma typically presents mutations disrupting normal TP53 gene function, frequently in the form of structural rearrangements that separate the promoter region from the coding parts of the gene. To unravel the consequences of a TP53 promoter relocated in this manner, we performed in-depth genetic analyses of osteosarcoma biopsies (n=148) and cell models. We show that TP53 structural variations not only facilitate further chromosomal alterations, but also allow the constitutively active TP53 promoter to upre... More

关键词